This Edition
ARTICLE | Clinical News
Vantas histrelin implant regulatory update
WIR Staff
October 18, 2004 7:00 AM UTC
FDA approved an NDA for Vantas, a 12-month histrelin implant, to treat advanced prostate cancer. ...